Posted on February 28, 2019 by Sitemaster
In a not entirely surprising set of findings, data from a relatively large registry study — to be presented at an upcoming meeting of the American Association of Cancer Research (AACR) — suggest that treatment with abiraterone acetate raises risk for cardiovascular-related mortality among prostate cancer patients with known cardiovascular risk factors. … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, cardiovascular, hospitalizaton, mortality, real world, risk, trials | 4 Comments »
Posted on May 25, 2017 by Sitemaster
Apparently the National Cancer Institute (NCI) has just re-funded the Fred Hutchinson Cancer Research Center in Seattle to the tune of $24 million to continue to operate what we see as an important, patient-centric program here in the USA that we (and therefore probably many others) were utterly unaware of. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: clinical, help, information, support, trials | 2 Comments »
Posted on July 14, 2016 by Sitemaster
Readers with an interest in how we got to today’s clinical trials processes for evaluating new drugs for the treatment of prostate cancer and other diseases might be surprised by what’s in an article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Drugs in development | Tagged: development, drug, marketing, regulation, trials | 2 Comments »
Posted on May 16, 2016 by Sitemaster
A report posted on line in European Urology has provided us with important clinical data related to the potential of this investigational drug in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: apalutamide, ARN-509, outcomes, trials | Leave a comment »
Posted on April 6, 2016 by Sitemaster
Johnson & Johnson has just acquired the rights to develop and sell a drug called niraparib for the treatment of prostate cancer everywhere in the world except Japan. The developer, Waltham, MA-based Tesaro, has retained the rights to niraparib in Japan. … READ MORE …
Filed under: Drugs in development | Tagged: advanced, inhibitor, niraparib, PARP, trials | Leave a comment »
Posted on February 23, 2016 by Sitemaster
Several readers will be interested in looking through a new article that deals with the recommendations from the Prostate Cancer Clinical Trials Working Group 3 on the development of clinical trials of new drugs to treat castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, CRPC, future, metastatic, trials | Leave a comment »
Posted on May 1, 2015 by Sitemaster
An article in the April issue of Lancet Oncology has provided additional data from the randomized, double-blind Phase III PREVAIL trial of enzalutamide versus placebo in men with asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: evidence, quality of life, survival, trials | Leave a comment »
Posted on September 10, 2012 by Sitemaster
If one is to believe a recent blog post on ACCCBuzz (promoting the upcoming annual meeting of the Association of Community Cancer Centers), the average community-based medical oncologist (not to mention the average community-based urologist) apparently makes little attempt to implement high quality guidance about quality of life for men with prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: care, quality of life, responsibility, trials | Leave a comment »
Posted on May 22, 2012 by Sitemaster
An article in The Washington Post today discusses an initiative through which a group of about 40 specialists in the management of advanced forms of genitourinary cancers (including prostate cancer) get together to share ideas and knowledge to help their patients. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, GUMDROP, referral, trials | Leave a comment »
Posted on February 9, 2012 by Sitemaster
Has the clinical success of some new drugs started to affect enrollment in trials of others for advanced forms of prostate cancer? … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ipilimumab, TAK-700, tasquinimod, trials | Leave a comment »
Posted on August 29, 2011 by Sitemaster
The national rates of participation in clinical trials by cancer patients have never been particularly high. The National Cancer Institute states that, “less than 5 percent of adults diagnosed with cancer each year will get treated through enrollment in a clinical trial.” … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficiency, enrollment, post-surgery, trials | 1 Comment »
Posted on January 24, 2011 by Sitemaster
An article by Mohler and Pantuck, published on line last week in the Journal of Urology, provides two perspectives on the future potential of abiraterone acetate in the treatment of prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, androgens, castration-resistant, CRPC, intermittent, mechanism of action, metastatic, trials | 12 Comments »
Posted on March 7, 2009 by Sitemaster
This weekend’s news includes items on:
- The ongoing major prostate cancer screening trials
- The changing landscape of first-line management for early stage, low risk prostate cancer
- Outcomes of RALP procedures in which surgical fellows participate
- Hypofractionation procedures in radiotherapeutic treatment
- The current state of sexual rehabilitation post-prostatectomy … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, focal therapy, hypofractionation, outcomes, RALP, screening, sexual rehabilitation, training, trials | 2 Comments »
Posted on September 22, 2008 by Sitemaster
Prostate cancer reports from the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), being held in Boston, are kindly provided by Eyad Abu-Isa, MD, a resident in radiation oncology at the University of Michigan.
This afternoon, new and updated data from three large Phase III clinical trials were presented at the ASTRO plenary session and clinical updates section. … READ MORE …
Filed under: Management, Treatment | Tagged: antiandrogens, clinical, radiotherapy, trials | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 